Pomerantz LLP

Please review this complaint. Click to Contact Us about joining this ACTION >>

Questions? Ask Us

AbbVie, Inc.

Pomerantz LLP is investigating claims on behalf of investors of AbbVie Inc. (“AbbVie” or the “Company”). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether AbbVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

On May 30, 2018, at approximately 8:00 am Eastern Standard Time, AbbVie announced preliminary results of a previously announced modified Dutch auction to repurchase the Company’s securities (the “Dutch Tender Offer”), stating that a total of 75.7 million shares were tendered at or below the purchase price of $105 per share.  Then, at approximately 4:45 pm on May 30, 2018, AbbVie announced “updated preliminary results” of the Dutch Tender Offer, stating that a total of 74.0M shares of AbbVie’s common stock had been tendered and not properly withdrawn at or below the lower purchase price of $103 per share.  On this news, AbbVie’s share price fell $4.07, or 3.95%, to close at $98.94 on May 31, 2018.